)
William Rust, PhD
CEO
Seraxis Inc
Will Rust is the co-founder and CEO of Seraxis Inc. After raising seed funds to launch Seraxis in 2013, he engineered a stem cell line with enhanced pancreatic differentiation potential as a basis for anti-diabetes islet replacement therapy. Seraxis subsequently completed three rounds of VC funding and developed cGMP manufacturing of highly pure and potent replacement pancreatic islets (SR-02). Seraxis received IND clearance for a phase 1/2 clinical study of SR-02 in late 2024. In parallel, Seraxis has developed two proprietary methods of immune evasion to enable implant of its lab-grown islets in non-immune-suppressed patients. Prior to launching Seraxis, Will spent most of his scientific career developing research tools and therapies from embryonic and iPS cells.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}